Drugs.com - Clinical Trials

Chimerix Updates the World Health Organization and the Global Health Security Initiative on Development of CMX001 as a Broad-Spectrum Therapeutic for Smallpox

Fri, 06 Nov 2009 20:02:56 GMT

RESEARCH TRIANGLE PARK, N.C., Nov. 6 /PRNewswire/ -- Chimerix, Inc., a biopharmaceutical company advancing orally-available antiviral therapeutics to address life-threatening diseases, presented updates on the development of the company's...

NexBio Publishes Two Articles Showing DAS181 (Fludase) Potently Inhibits Pandemic Influenza A(H1N1) and NAI-Resistant Influenza Viruses

Fri, 06 Nov 2009 19:58:27 GMT

SAN DIEGO, Nov. 6 /PRNewswire/ -- NexBio Inc., in collaboration with scientists at the Centers for Disease Control and Prevention (CDC), St. Louis University, and the University of Hong Kong, announced today the publication of two articles in...

Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting

Fri, 06 Nov 2009 19:58:11 GMT

ITCA 650 induces potent reductions of HbA1c and body weight after 4 week treatment; ITCA 650 delivers up to 12 months of exenatide therapy from a single DUROS device HAYWARD, Calif., Nov. 6 /PRNewswire/ -- Intarcia Therapeutics, Inc. delivered two...

Oncolytics Biotech Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting

Fri, 06 Nov 2009 19:38:57 GMT

Oncolytics Biotech® Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting CALGARY, AB, November 6, 2009 - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) (“Oncolytics” or the “Company”)...

ZIOPHARM Presents Positive Palifosfamide Sarcoma Randomized Phase II Interim Data at Annual Meeting of the Connective Tissue Oncology Society

Fri, 06 Nov 2009 12:27:09 GMT

-- Palifosfamide prolongs progression-free survival by at least 50% -- NEW YORK--(BUSINESS WIRE)--Nov 6, 2009 - ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) presented today at the 15th Annual Connective Tissue Oncology Society (CTOS) Meeting, positive...

Valeant Pharmaceuticals Highlights Taribavirin Phase IIb End of Study Data Presentation at American Association for the Study of Liver Disease (AASLD) Annual Meeting

Thu, 05 Nov 2009 18:56:11 GMT

ALISO VIEJO, Calif., Nov. 3 /PRNewswire-FirstCall/ -- Valeant Pharmaceuticals (NYSE: VRX) today announced that results from the week-72 analysis for its Phase IIb dose-finding clinical trial for taribavirin, a prodrug of ribavirin which is in...

New Data on Bendamustine Offers Hope to Non-Hodgkin's Lymphoma Patients Resistant to Standard Therapy

Thu, 05 Nov 2009 18:55:55 GMT

Cambridge (United Kingdom), 5 November 2009: New data published today in the journal, Cancer, reveals that three quarters (75%) of patients with indolent B-cell non-Hodgkin’s lymphoma (iNHL), responded to treatment with Bendamustine following a...

Journal Cancer Publishes Pivotal Study of TREANDA in Patients with in Relapsed Indolent NHL

Thu, 05 Nov 2009 18:49:55 GMT

Frazer, Pa. – November 5, 2009 – Cephalon, Inc. (Nasdaq: CEPH) today announced the journal Cancer has published a pivotal study demonstrating that TREANDA® (bendamustine HCl) for Injection induced durable responses in patients with...

New Safety Data on Menactra for Infants

Thu, 05 Nov 2009 17:15:49 GMT

Sanofi Pasteur Presents Safety Data on Menactra® Vaccine Given to Infants at Infectious Disease Society Meeting The two-dose meningococcal quadrivalent conjugate vaccine was generally well-tolerated Philadelphia, PA – November 2, 2009...

M. D. Anderson News Release: Early Stage, HER2 Positive Breast Cancer Patients at Increased Risk of Recurrence

Thu, 05 Nov 2009 15:55:40 GMT

Large study finds subset of women that may need additional therapy HOUSTON , Nov. 2, 2009- Early-stage breast cancer patients with HER2 positive tumors one centimeter or smaller are at significant risk of recurrence of their disease, compared...

Approved Lymphoma Drug Shows Promise in Early Tests Against Bone Cancer

Thu, 05 Nov 2009 15:20:09 GMT

ROCHESTER, N.Y., Nov. 5 /PRNewswire-USNewswire/ -- A drug already approved for the treatment of lymphoma may also slow the growth of the most deadly bone cancer in children and teens, according to an early-stage study published online today in...

Amgen Announces Overall Survival Results for Vectibix in First-Line Metastatic Colorectal Cancer

Thu, 05 Nov 2009 14:35:12 GMT

Phase 3 Results Reinforce Importance of KRAS Status THOUSAND OAKS, Calif., Nov. 5 /PRNewswire-FirstCall/ -- Amgen (NASDAQ: AMGN) today announced that the Phase 3 PRIME "203" trial evaluating Vectibix® (panitumumab) administered in...

Ocera Therapeutics Presents Clinical Data Demonstrating AST-120 Relieves Pruritus in Patients with Liver Cirrhosis at the 60th Annual AASLD Meeting

Thu, 05 Nov 2009 14:21:31 GMT

AST-120 Also Shown to Reduce Ammonia and Brain Swelling in Rat Model of Cirrhosis BOSTON, Nov. 2 /PRNewswire/ -- Ocera Therapeutics, Inc. announced today that AST-120 (spherical carbon adsorbent) was shown to reduce the severity of pruritus...

BioVex Announces Publication of Phase 2 Melanoma Results With OncoVEX (GM-CSF) in the Journal of Clinical Oncology

Thu, 05 Nov 2009 13:51:10 GMT

Complete durable eradication of disease achieved in a significant number of patients with investigational therapy for advanced Stage III and Stage IV melanoma WOBURN, Mass., Nov. 2 /PRNewswire/ -- BioVex Inc, a company developing new generation...

Short-Term Hormone Therapy Added to Radiation Increases Survival for Medium-Risk, But Not Low-Risk, Prostate Cancer Patients

Thu, 05 Nov 2009 13:45:20 GMT

CHICAGO, Nov. 2 /PRNewswire-USNewswire/ -- Short-term hormone therapy given prior to and during radiation treatment to medium-risk prostate cancer patients increases their chance of living longer, compared to those who receive radiation...

Chelation Therapy Drug Found Safe and Beneficial for Children With Autism

Thu, 05 Nov 2009 13:02:44 GMT

The Autism Research Institute calls for further investigations into the use of chelation therapy for individuals with autism SAN DIEGO, Nov. 5 /PRNewswire-USNewswire/ -- Two studies published by the Southwest College of Naturopathic Medicine in...

Significantly More Smokers With Mild-To-Moderate COPD Quit Smoking Using CHANTIX/CHAMPIX (Varenicline) Compared With Placebo

Thu, 05 Nov 2009 12:58:17 GMT

Findings from Pfizer-Sponsored Study Presented as Late-Breaker at American College of Chest Physicians Annual Meeting SAN DIEGO--(BUSINESS WIRE)--Nov 4, 2009 - New study results showed that 42.3 percent of smokers with mild-to-moderate...

Alnylam Presents New Pre-Clinical Data on RNAi Therapeutics at Oligonucleotides Therapeutics Society (OTS) Meeting

Thu, 05 Nov 2009 12:15:14 GMT

– Research Findings Include Rational Design of Mimetic Lipoprotein Particles (MLPs), a Novel Delivery Technology, New Data Regarding Potency of RNAi-Mediated Gene Silencing, and an Update on RNA Activation Research Efforts – CAMBRIDGE,...

Thirteen Abstracts Featuring Exelixis Compounds Accepted for Presentation at the 2009 AACR-NCI-EORTC International Conference

Wed, 04 Nov 2009 20:40:31 GMT

Includes Clinical Data for XL147, XL765 and XL139 SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Nov 4, 2009 - Exelixis, Inc. (Nasdaq: EXEL) announced today that thirteen abstracts related to the company's development candidates have been accepted...

Concerta in the Classroom: New Data on Attention in Children With ADHD

Wed, 04 Nov 2009 19:53:57 GMT

LAS VEGAS, Nov. 4 /PRNewswire/ -- New findings presented today show that CONCERTA® (OROS® methylphenidate HCl Extended-Release Tablets CII) is the only stimulant medication with data that demonstrate a significant treatment effect on...

New Data on Attention in Children with ADHD

Wed, 04 Nov 2009 19:26:29 GMT

LAS VEGAS, Nov. 4, 2009 – New findings presented today show that CONCERTA® (OROS® methylphenidate HCl Extended-Release Tablets CII) is the only stimulant medication with data that demonstrate a significant treatment effect on attention at...

Aeolus Pharmaceuticals' AEOL 10150 Protects Lungs Against Chlorine Gas Exposure in Animal Studies

Wed, 04 Nov 2009 19:20:45 GMT

Data Supports Compound's Potential as a Countermeasure for Chlorine Gas Exposure MISSION VIEJO, Calif.--(BUSINESS WIRE)--Nov 4, 2009 - Aeolus Pharmaceuticals, Inc. (OTCBB: AOLS) reported that researchers from National Jewish Health and McGill...

Promedior Announces Publication of Preclinical Studies in Science Translational Medicine Demonstrating that hSAP Inhibits Kidney Fibrosis

Wed, 04 Nov 2009 19:15:32 GMT

MALVERN, Pa.--(BUSINESS WIRE)--Nov 4, 2009 - Promedior, Inc., a leader in the development of novel therapeutics for the treatment of fibrotic diseases and tissue remodeling, announced today the publication of results from preclinical studies...

Long-term Outcomes Data Validates the Utility of PROSTASCINT in Guiding Targeted Prostate Cancer Treatment and Predicting Disease Free Survival

Wed, 04 Nov 2009 14:01:11 GMT

LANGHORNE, Pa., Nov. 4 /PRNewswire/ -- EUSA Pharma announced that PROSTASCINT® (capromab pendetide) fusion imaging was shown to effectively guide prostate cancer therapy targeting and dosing and is a significant predictor of disease free...

New Phase IIa data on TMC435 in patients with hepatitis C presented at the ongoing AASLD - meeting

Wed, 04 Nov 2009 13:43:35 GMT

STOCKHOLM, Nov. 4, 2009--Data were presented from the phase IIa trial (OPERA-1) for TMC435 at the ongoing 60th annual meeting of the American Association for the Study of Liver Diseases in Boston, USA. TMC435 is an investigational protease...

Data for EntreMed's ENMD-2076 to Be Presented at the Upcoming AACR-NCI-EORTC Conference

Tue, 03 Nov 2009 21:16:19 GMT

Data from the ENMD-2076 Phase 1 Leukemia Trial to be Included ROCKVILLE, Md., Nov. 3 /PRNewswire-FirstCall/ -- EntreMed, Inc. (NASDAQ: ENMD) , a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer...

INFORM-1 Results: Robust Antiviral Suppression Achieved with Combination of Nucleoside Analog Polymerase Inhibitor RG7128 and Protease Inhibitor RG7227

Tue, 03 Nov 2009 20:52:19 GMT

- Significant antiviral potency in both naive and treatment-failure patients - BOSTON, Nov. 3 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) and Pharmasset, Inc. (Nasdaq: VRUS) today...

Ironwood and Forest Announce Positive Linaclotide Results from Two Pivotal Phase 3 Trials in Patients with Chronic Constipation

Tue, 03 Nov 2009 20:41:58 GMT

Top-line Results Show Each Trial Met Primary and All Secondary Endpoints CAMBRIDGE, Mass. & NEW YORK--(BUSINESS WIRE)--Nov 3, 2009 - Ironwood Pharmaceuticals, Inc. and Forest Laboratories, Inc. (NYSE: FRX) today announced positive top-line...

ARIAD's AP24534 Featured in Cancer Cell Publication as a Potential First-in-Class Pan BCR-ABL Inhibitor

Tue, 03 Nov 2009 20:35:14 GMT

~Paper Features Design and Preclinical Characterization of AP24534 ~ Data Demonstrate Inhibition of all Known Variants of the CML Target Protein CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov 2, 2009 - ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA)...

SCYNEXIS' SCY-635 Demonstrates Positive Antiviral Activity in Combination with Approved and Investigational Anti-HCV Agents

Tue, 03 Nov 2009 20:26:09 GMT

--In Vitro Results presented in a poster session at AASLD; Phase 2 combination studies to be initiated in 2Q 2010-- RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Nov 3, 2009 - Drug discovery company SCYNEXIS, Inc. today presented positive...

MagForce Nanotechnologies AG reaches primary study endpoint in pivotal glioblastoma study

Tue, 03 Nov 2009 19:48:15 GMT

BERLIN--(BUSINESS WIRE)--Nov 3, 2009 - MagForce Nanotechnologies AG has successfully completed its single-arm clinical trial on the efficacy of thermotherapy using superparamagnetic nanoparticles in patients with recurrent glioblastoma. The...

Idera Pharmaceuticals Presents Preclinical Data on IMO-2125, its Lead Drug Candidate for Chronic Hepatitis C Virus Infection, at Liver Meeting 2009

Tue, 03 Nov 2009 16:36:17 GMT

- IMO-2125 Induces Endogenous Interferons and Other Antiviral Proteins - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov 3, 2009 - Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today presents preclinical data on the mechanism by which IMO-2125 was shown...

Study Finds Lack of Diffusible VEGF Growth Factor Can Cause Retinal Defects Similar to Dry Macular Degeneration

Tue, 03 Nov 2009 13:21:02 GMT

Discovery may also have impact on the use of new drugs for wet macular degeneration BOSTON, Nov. 2 /PRNewswire-USNewswire/ -- Scientists at Schepens Eye Research Institute have found that when the eye is missing a diffusible form of vascular...

Sanofi Pasteur Presents Safety Data on Menactra Vaccine Given to Infants at Infectious Disease Society Meeting

Tue, 03 Nov 2009 13:15:07 GMT

The two-dose meningococcal quadrivalent conjugate vaccine was generally well-tolerated PHILADELPHIA, Nov. 2 /PRNewswire/ -- Sanofi Pasteur, the vaccines division of sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), presented Safety of a...

Mayo Clinic Proceedings Publishes Study of NUVIGIL in Patients with Shift Work Disorder

Mon, 02 Nov 2009 23:26:44 GMT

FRAZER, Pa., Nov. 2 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) today announced that the November issue of Mayo Clinic Proceedings has published data from a pivotal Phase III trial demonstrating that NUVIGIL® (armodafinil) Tablets...

Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C

Mon, 02 Nov 2009 23:23:49 GMT

Interim results of Phase IIa NEXT-I study presented at American Association for the Study of Liver Diseases (AASLD) Annual Meeting BOSTON, Nov. 2 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today reported that interim...

NovaBay's Aganocides Show Penetration and Efficacy in a Pre-Clinical Infected Human Nail Model of Onychomycosis

Mon, 02 Nov 2009 21:16:55 GMT

Data to be presented at Infectious Diseases Society of America Conference EMERYVILLE, Calif., Oct. 30 /PRNewswire-FirstCall/ -- NovaBay Pharmaceuticals, Inc. (NYSE-Amex: NBY) today announced that its Aganocide® compounds demonstrate potent...

FibroGen Announces New Research in Anti-CTGF and HIF-PHI Therapeutic Development Programs in Kidney Disease

Mon, 02 Nov 2009 20:52:57 GMT

— Data Presented at the 42nd Annual Meeting of the American Society of Nephrology — SAN FRANCISCO--(BUSINESS WIRE)--Nov 2, 2009 - FibroGen, Inc. today announced that new research on its therapeutic development programs in kidney disease...

BARACLUDE (entecavir) Demonstrated Greater Antiviral Efficacy Compared to Adefovir in New Study of Chronic Hepatitis B Patients with Evidence of Decompensated Cirrhosis

Mon, 02 Nov 2009 20:40:41 GMT

Study Addresses Unmet Medical Need for Difficult-to-Treat Patient Population BOSTON--(BUSINESS WIRE)--Oct 31, 2009 - Bristol-Myers Squibb (NYSE: BMY) today announced 48-week data from an ongoing study (ETV-048) of chronic hepatitis B...

Bristol-Myers Squibb and ZymoGenetics Present Final Phase 1b Results for PEG-Interferon Lambda in Hepatitis C

Mon, 02 Nov 2009 20:33:19 GMT

Antiviral activity seen at all dose levels tested Results support moving to dose-ranging Phase II studies in treatment-naïve HCV patients PRINCETON, N.J. & SEATTLE--(BUSINESS WIRE)--Oct 31, 2009 - Bristol-Myers Squibb Company (NYSE:...